KAIROS PHARMA, LTD. Deferred Costs, Noncurrent
KAIROS PHARMA, LTD. (KAPA) had Deferred Costs, Noncurrent of $1.28 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredCosts · last filed 2026-08-12
- 2026-06-30: Deferred Costs, Noncurrent $1.28M.
- 2026-03-31: Deferred Costs, Noncurrent $1.28M.
- 2025-12-31: Deferred Costs, Noncurrent $1.09M.
- 2025-09-30: Deferred Costs, Noncurrent $1.31M.
| Period end | Deferred Costs, Noncurrent |
|---|---|
| 2026-06-30 | $1.28M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $1.28M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $1.09M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $1.31M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $1.69M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $1.71M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $1.38M 10-K · filed 2026-03-31 |
| 2023-12-31 | $482.00K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |